FDA Grants EUA For Access Bio’s Lateral Flow COVID-19 Antigen Test

Access Bio joins Abbott as the second company with FDA authorization to distribute PCR, antigen and antibody tests for COVID-19.

3D_Coronavirus
• Source: shutterstock.com

The US Food and Drug Administration has granted an emergency use authorization (EUA) for Access Bio, Inc.’s CareStart lateral-flow COVID-19 antigen test, the company announced on 13 October.

The CareStart test is a lateral flow immunochromatographic assay for detecting the antigen to the SARS-CoV-2 virus in nasopharyngeal swab specimens collected from the patient at the point of care...

More from In Vitro Diagnostics

More from Diagnostics